Skye Bioscience Sees 22.3% Weight Loss, Plans Higher Doses After 200 mg Underexposure
Namasimab combined with semaglutide produced a 22.3% mean weight loss over 52 weeks with placebo-like tolerability and no neuropsychiatric events. The 200 mg weekly dose proved underexposed in peripheral tissues, prompting higher-dose data by Q4 2026 and development of a Halozyme-based subcutaneous formulation.
1. Obesity Program Efficacy
Namasimab, the first CB1 monoclonal antibody for obesity, achieved a 22.3% mean weight loss over 52 weeks when combined with semaglutide, with no observed neuropsychiatric events and placebo-like safety profile across dose cohorts.
2. Dose Exposure Challenges
Pharmacokinetic analysis revealed that the 200 mg weekly dose of namasimab was underexposed in peripheral tissues, leading Skye Bioscience to initiate Part C of the CBond study for higher-dose evaluation and expect data by Q4 2026.
3. Delivery Formulation Collaboration
Skye is collaborating with Halozyme on a mix-and-deliver co-formulation for high-volume subcutaneous injections and is developing an auto-injector component in preparation for Phase 2B and Phase 3 trials.